Homozygous or compound heterozygous mutations in *HSD17B4* (MIM \#601860) are responsible for D-bifunctional protein (DBP) deficiency (MIM \#261515), a disorder of peroxisomal fatty acid oxidation; very-long-chain fatty acids (VLCFAs) are one of the substrates of DBP. DBP has multiple enzymatic activities^[@R1],[@R2]^ and contains 3 domains: dehydrogenase, hydratase, and sterol carrier protein-2. DBP deficiency is classified into 3 subtypes (type I--III) depending on the affected domain and consequent enzymatic activity.^[@R3]^ All types present during infancy as severe hypotonia, seizures, and dysmorphic features. Diagnosis is based on confirmation of elevated plasma VLCFA levels. Most patients with DBP deficiency die before age 2 years.

Mutations of the *HSD17B4* gene also cause juvenile-onset DBP deficiencies^[@R4][@R5][@R8]^ and Perrault syndrome.^[@R9][@R10][@R11]^ As both clinical phenotypes overlap and are less severe than those of infant-onset DBP deficiencies, patients with these disorders survive until adolescence/adulthood. Patients with juvenile-onset DBP deficiencies and Perrault syndrome present with hearing loss, cerebellar ataxia, peripheral neuropathy, infertility, and normal plasma VLCFA levels.

We describe patients with a slowly progressive spinocerebellar ataxia, autosomal recessive (SCAR) in middle age. Genetic analysis implicated *HSD17B4* as the causative gene. Although reports on juvenile-onset DBP deficiency with mild symptoms have increased, middle age--onset DBP deficiency has not been previously reported. We confirmed a reduction in DBP with in vitro assays and compared the severity of DBP deficiency with those caused by previously reported mutations.

Methods {#s1}
=======

Standard protocol approvals and patient consents {#s1-1}
------------------------------------------------

This study was approved by the Human Subjects Committees of Hiroshima University. Written informed consent was obtained from all subjects. Clinical details were collected from medical records and interviews.

Patients {#s1-2}
--------

We enrolled 2 Japanese families with autosomal recessive traits for cerebellar ataxia. Family 1 was from Kagawa, Shikoku; family 2 was from Kagoshima, South of Kyusyu. Families 1 and 2 included 3 and 2 affected individuals, respectively ([figure 1A](#F1){ref-type="fig"}). Blood samples were obtained from 2 affected individuals in family 1 and from 2 affected and 3 unaffected individuals in family 2. All patients were diagnosed with slowly progressive spinocerebellar ataxia by neurologists. Before this study, we confirmed that all affected individuals had no pathogenic mutations of SCA1, 2, 3, 6, 7, 8, 31, 36, and dentatorubral-pallidoluysian atrophy.

![Identification of mutations in HSD17B4, encoding DBP, in families with SCAR\
(A) Pedigrees in families 1 and 2, both of which had consanguineous marriages. Affected individuals are indicated by filled circles or squares. (B) Brain MRI of 3 patients (1-IV-2 at age 65 years, 1-IV-3 at age 65 years, and 2-IV-1 at ages 52 and 71 years): upper, T1-weighted axial images; lower, T1-weighted sagittal images. Cerebellar atrophy was observed. (C) Homozygosity fingerprinting of 4 individuals (family 1, 1-IV-2 and 1-IV-3; family 2, 2-IV-1 and 2-IV-2). Black bars indicate IBD. Relatively long segments of IBD were found in chromosome 5. (D) Sanger sequencing of mutations in HSD17B4 of a patient (2-IV-2); her unaffected sister was used as a control (2-IV-3). The mutation segregated with the phenotype in the family members. (E) Domain architecture of DBP with the mutation. DBP = D-bifunctional protein; IBD = identity by descent; SCAR = spinocerebellar ataxia, autosomal recessive.](NG2019010918f1){#F1}

Homozygosity fingerprinting, exome sequencing, and variant filtering {#s1-3}
--------------------------------------------------------------------

Single nucleotide polymorphism (SNP) genotyping was performed using the Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA). We used homozygosity fingerprinting to obtain the identity by descent (IBD).^[@R12]^ Exome sequencing was performed using 2 samples from patients, 1-IV-2 and 2-IV-1 ([figure 1A](#F1){ref-type="fig"}), as previously described.^[@R13]^ More than 100,000 variants in each sample were called. We filtered the candidate variants based on open databases (dbSNP v151, the 1000 Genomes Project, and Exome Sequencing Project), genomic position, function, and zygosity. Variants observed in the in-house database were excluded. We selected the variants localized in the region isolated from the homozygosity fingerprinting. Functional predictions due to amino acid changes were estimated using PolyPhen-2,^[@R14]^ SIFT,^[@R15]^ MutationTaster,^[@R16]^ and the Combined Annotation-Dependent Depletion (CADD).^[@R17]^ All reported genomic coordinates were in GRCh37/hg19. Candidate variants were confirmed by Sanger sequencing (ABI3130; Thermo Fisher Scientific, Waltham, MA).

Cell culture {#s1-4}
------------

Skin biopsies were performed to obtain fibroblasts from 2 patients, 1-IV-2 and 2-IV-1, and from healthy controls. Fibroblasts were grown in Dulbecco Modified Eagle Medium, containing 10% fetal bovine serum, 100 U/mL of penicillin, and 100 μg/mL of streptomycin, under humidified air at 37°C in 5% CO~2~.

Western blotting {#s1-5}
----------------

Fibroblasts were lysed with ice-cold RIPA buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, protease inhibitors, and phosphatase inhibitors). The samples were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (PAGE) and transferred to a PVDF membrane (Bio-Rad, Hercules, CA). Membranes were blocked with 5% non-fat milk and then incubated with anti-HSD17B4 (1:250, HPA021302; Atlas Antibodies, Stockholm, Sweden), anti-PMP70 (1:500, SAB4200181; Sigma-Aldrich, St. Louis, MO), anti-ß-actin (1:2000, sc-47778; Santa Cruz Biotechnology, Dallas, TX), and anti-α tubulin (1:25000, 11224-1-AP; Proteintech, Rosemont, IL) primary antibodies. The immunoreactive bands were detected with LAS-4000 (GE Healthcare, Chicago, IL). The quantitative densitometric analyses were performed with Image Quant LAS 4000 software (GE Health care). Blue native PAGE (BN-PAGE) analysis was performed using the NativePAGE Novex Bis-Tris Gel System (Life Technologies, Carlsbad, CA). We used the NativePAGE 4--16% Bis-Tris Protein Gel (Life Technologies). Fibroblasts were lysed with ice-cold lysis buffer (50 mM bis-tris \[HCl\], pH 7.2, 50 mM NaCl, 10% glycerol, 0.001% Ponceau S, 1% digitonin, protease inhibitors, and phosphatase inhibitors).

Quantitative reverse transcription PCR {#s1-6}
--------------------------------------

Total RNA was extracted from fibroblasts using the RNeasy Mini Kit (Qiagen, Hilden, Germany). Complementary DNA was generated using oligo-d(T) primers and the ReverTra-Plus kit (Toyobo, Osaka, Japan). Quantitative real-time expression analysis was performed using THUNDERBIRD SYBR qPCR Mix (Toyobo) on the StepOnePlus Real-Time PCR system (Thermo Fisher Scientific). We used the standard curve quantification method with *GAPDH* as the reference gene. Primers are as follows: GAPDH-Fw, GAAGGTGAAGGTCGGAGTCAACG; GAPDH-Rv, GAAGATGGTGATGGGATTTCC; HSD17B4-Fw, AGTTGCTTTTGATAGGTGCAG; and HSD17B4-Rv, AAAGCTCATTCCACATAGGTTTG.

Immunocytochemistry and confocal microscopy {#s1-7}
-------------------------------------------

Fibroblasts were fixed with 4% paraformaldehyde and stained with anti-HSD17B4 (1:50, HPA021302; Atlas Antibodies) and anti-PMP70 (1:250, SAB4200181; Sigma-Aldrich) antibodies. Anti-rabbit IgG Alexa Fluor 594 and anti-mouse IgG Alexa Fluor 488 (1:500; Thermo Fisher Scientific) were used as secondary antibodies. Immunostained cells were examined using a confocal microscope (LSM800; Carl Zeiss, Jena, Germany). Intensities were analyzed using ImageJ.

In silico modeling {#s1-8}
------------------

Three-dimensional experimental structures were retrieved from the Protein Data Bank (PDB) and analyzed with PyMOL.

Collection of clinical data and pathogenicity scoring {#s1-9}
-----------------------------------------------------

Previously reported mutations and clinical data were collected from the literature^[@R4][@R5][@R11],[@R18][@R19][@R24]^ and ClinVar. Mutations were used if they were reported with sufficient clinical detail. Selected mutations were divided into 3 groups based on age at onset ([table 1](#T1){ref-type="table"}): infant onset, under 2 years; juvenile onset, from 2 to 19 years; and adult onset, over 20 years. The pathogenicity of the mutations was assessed with CADD.
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Statistics {#s1-10}
----------

Numerical data are indicated as the mean ± standard error of mean or as the mean ± SD. The Student *t* test was used for statistical analysis in immunocytochemical experiments. The Tukey HSD test was used in Western blotting and quantitative reverse transcription PCR (RT-qPCR) experiments. Differences in CADD scores among the 3 groups were assessed with the Kruskal-Wallis test. The level of significance was set at *p* \< 0.05.

Data availability {#s1-11}
-----------------

The protocol and the statistical analysis plan are available on request.

Results {#s2}
=======

Clinical description {#s2-1}
--------------------

The 2 affected individuals of family 1 (1-IV-1 and 1-IV-2) were born from consanguineous parents. Neither had motor function abnormalities during their childhood. The older sister (1-IV-1) developed gait disturbance at age 33 years and the younger sister (1-IV-2) at age 35 years, whereas previously reported patients with adult-onset DBP deficiency developed ataxia by age 30 years. The younger woman had 2 miscarriages and secondary amenorrhea at age 35 years, and neither patient had any children. She developed hearing loss in her 30s and dysarthria at age 38 years and experienced difficulty writing at age 39 years. Her cognitive function was normal. She exhibited horizontal nystagmus and saccadic eye movement without limitations. Although dysarthria was observed, there was no obvious dysphagia. Other neurologic symptoms included severe bilateral sensorineural hearing loss, ataxia of the upper and lower limbs, and difficulty transferring from sit to stand and walking. Observed reflexes were normal, and no abnormalities of the sensory system or autonomic nervous system were observed. Progression of the cerebellar ataxia was very slow. She was able to walk without assistance until age 66 years when she began using a wheelchair. This is much later than other patients with adult-onset DBP deficiency who require wheelchairs by their 30s. MRI of the brain indicated mild cerebellar atrophy without midbrain and pons atrophy ([figure 1B](#F1){ref-type="fig"}). The symptoms of the older sister were similar to those of the younger one. A cousin of the affected sisters was a male offspring of family 1 (1-IV-3). He was also born from consanguineous parents. No abnormalities in motor function were observed in his childhood. He developed gait disturbance at age 39 years. He has one healthy son. His symptoms progressed slowly, and he began using a wheelchair in his 60s. His neurologic findings showed horizontal nystagmus and saccadic eye movement without limitations. He exhibited ataxia in the upper and lower limbs, action tremor, and terminal tremor, but no muscle weakness or sensory disturbances. His clinical diagnosis is slowly progressive spinocerebellar degeneration. MRI of the brain showed cerebellar atrophy ([figure 1B](#F1){ref-type="fig"}).

The male patient of family 2 (2-IV-1) was a son of neurologically healthy, consanguineous parents. He was aware of mild deafness at age 40 years. His age at onset of ataxia was 49 years. His initial symptoms were gait disturbance and dysarthria. He exhibited neuronal hearing loss in both ears, mild dysarthria, upper and lower limb and trunk ataxia, terminal tremor, and decreased sensation of vibration in the lower limbs. MRI of the brain indicated mild progressive cerebellar atrophy without pons atrophy ([figure 1B](#F1){ref-type="fig"}). Biochemical examinations were performed: plasma levels of VLCFAs were normal; the C24:0/C22:0 ratio was 0.687 (mean = 1.05, SD = 0.16); and the C26:0/C22:0 ratio was 0.028 (mean = 0.012, SD = 0.005). His sister (2-IV-2) was also affected and showed similar symptoms. Her age at onset of ataxia was 40 years, and she presented with the initial symptom of intention tremor. The patient developed hearing loss at age 46 years. She also exhibited slurred speech, neck tremor, titubation, and decreased sensation of vibration in the lower limbs. She had no nystagmus apart from saccadic eye movement. Although she had 2 sons, her age at menopause was 33 years. She was able to walk without assistance until she was age 60 years.

Homozygous mutation identification {#s2-2}
----------------------------------

From the result of homozygosity fingerprinting, a relatively long IBD segment existed in chromosome 5 in both families ([figure 1C](#F1){ref-type="fig"}). Furthermore, as the haplotypes of both families were shared, they may have been derived from the same ancestor. Exome sequencing identified 15 and 5 variants in each family, which were estimated to be pathogenic by at least one of the 3 prediction algorithms. Only one mutation was a common variant in both families: Chr5:118814617G\>A corresponding to *HSD17B4* (NM 000414):c.523G\>A, p.Ala175Thr ([figure 1, D and E](#F1){ref-type="fig"}). The mutation was located in the dehydrogenase domain of DBP ([figure 1E](#F1){ref-type="fig"}). Other mutations reported as causative genes of SCAR were not detected. Therefore, we concluded that *HSD17B4* was the most likely candidate. The CADD score of p.Ala175Thr was 11.6. Although p.Ala175Thr was previously reported as one of the compound heterozygous mutations (p.Arg132Trp/p.Ala175Thr),^[@R7]^ our case with a homozygous p.Ala175Thr mutation is very rare.

Reduction of the level of HSD17B4 proteins despite normal messenger RNA expression {#s2-3}
----------------------------------------------------------------------------------

We used an immunoblot assay to examine the expression of the HSD17B4 protein in our patients. Because the epitope of the anti-HSD17B4 antibody is at the N-terminal region of the protein (5--91aa), the antibody recognizes the full-length and the N-terminal 35 kD fragment of the protein. The full-length protein was significantly diminished relative to that of controls (∼40%) ([figure 2, A and B](#F2){ref-type="fig"}). The processed 35 kD dehydrogenase domain was also decreased (∼70%) ([figure 2, A and B](#F2){ref-type="fig"}). RT-qPCR indicated no reduction in the levels of the transcripts ([figure 2C](#F2){ref-type="fig"}). These results indicate that the steady-state level of the protein was reduced. Moreover, the ratios of HSD17B4 protein expression to PMP70, a peroxisome membrane protein, were decreased (figure e-1, [links.lww.com/NXG/A216](http://links.lww.com/NXG/A216)).

![Expression of HSD17B4 transcripts and proteins\
(A and B) Western blotting of lysates from the patients\' fibroblasts (1-IV-2 and 2-IV-1) and the healthy controls. (C) Quantitative reverse transcription PCR. The expression level of the mRNA in the patients (1-IV-2 and 2-IV-1) was not different from that of the healthy controls. (D) Dimerized DBP of the patients\' fibroblasts (1-IV-2 and 2-IV-1) was reduced in comparison with that of the healthy controls. Fibroblasts were solubilized with 1% digitonin and then analyzed by blue native-polyacrylamide gel electrophoresis followed by immunoblotting using anti-HSD17B4 and anti-α tubulin antibodies. Twenty-five micrograms per lane samples were loaded. The solid arrow indicates the dimerized DBP, and the open arrow shows the processed N-term fragment monomer. Molecular weight markers are shown on the right. Bar graph showed quantification of the level of HSD17B4 protein dimer using that of α tubulin as a loading control. Mean ± SEM. All experiments were repeated 3 or more times. \**p* \< 0.05, \*\**p* \< 0.01 DBP = D-bifunctional protein; mRNA = messenger RNA.](NG2019010918f2){#F2}

Distribution and quantification of HSD17B4 proteins in the patients\' fibroblasts {#s2-4}
---------------------------------------------------------------------------------

We stained fibroblasts using anti-HSD17B4 and anti-PMP70 antibodies ([figure 3A](#F3){ref-type="fig"}). HSD17B4 proteins were localized to the peroxisomes in both controls and patients. HSD17B4 was significantly decreased in the patients ([figure 3B](#F3){ref-type="fig"}).

![Confocal images of fibroblasts\
(A) Fibroblasts from a patient (1-IV-2) and a healthy control were immunostained with anti-HSD17B4 antibodies (red), anti-PMP70 (green) as a peroxisome marker, and DAPI (blue). The white dotted lines show the morphology of the fibroblasts. Scale bar is 20 µm. Enlarged images of the red boxed region are also shown in the upper left (scale bar is 1 μm). (B) Quantification of the intensities of HSD17B4 staining compared with PMP70 and of the intensities of HSD17B4 protein per puncta (n = 5 cells each). \**p* \< 0.05, \*\*\**p* \< 0.0001. DAPI = 4\',6-diamidino-2-phenylindole](NG2019010918f3){#F3}

Reduction in the dimerized HSD17B4 {#s2-5}
----------------------------------

Dimerization of HSD17B4 proteins is required for its enzymatic activity.^[@R25]^ We analyzed the levels of dimerized HSD17B4 proteins in fibroblasts by using BN-PAGE ([figure 2D](#F2){ref-type="fig"}). Dimerized proteins in the patients were significantly reduced relative to those in the healthy controls (∼40%). The pattern of oligomers differed between patients and controls.

Structure modeling by A175T mutation {#s2-6}
------------------------------------

p.Ala175 is conserved only among humans, gorillas, lizards, medakas, and zebrafish. The alanine residue found in these species is replaced with a cysteine or serine in other species ([figure 4A](#F4){ref-type="fig"}). The crystal structure of the dehydrogenase domain of human HSD17B4 (PDB: 1ZBQ) was used to assess the potential effects of the mutations ([figure 4B](#F4){ref-type="fig"}). The side chain of Ala175 is situated on the outer surface of the dimerized α helix.^[@R26]^ Unlike variants of cysteine or serine residues, mutation of a threonine residue results in an increased side chain volume and consequently altered packing that might affect the homodimer interaction ([figure 4C](#F4){ref-type="fig"}). Although the mutations do not directly affect residues in the active site, they potentially alter the stability of the dimer.

![Three-dimensional structure of the dehydrogenase domain\
(A) Conservation of the protein sequence at the mutation. Mutated residue is in red. (B) Crystal structure of the homodimeric dehydrogenase domain complex of DBP, taken from the Protein Database (id, 1ZBQ). Circle: dimerized region. (C) Magnification around Ala175 residue. The side chains of the Ala175 residue (red) and Thr191 residue are shown (purple). The side chain of Ala175Thr is closest to that of Thr191. The calculated black value (Å) indicates the distance between side chains having hydroxyl groups. This model shows the most frequent structure. DBP = D-bifunctional protein.](NG2019010918f4){#F4}

Comparison between mild A175T-induced symptoms and reports of severe mutations {#s2-7}
------------------------------------------------------------------------------

We calculated the CADD scores of the *HSD17B4* mutations previously reported and compared the scores of the 3 groups based on age at onset ([figure 5](#F5){ref-type="fig"} and table e-1, [links.lww.com/NXG/A217](http://links.lww.com/NXG/A217)). The CADD scores of the severe phenotypes tended to be higher than the milder ones. A mutation of p.Ala175Thr featured the lowest CADD score. The onset age of our patients was from 33 to 49 years, which encompasses older ages than those considered by previous reports. There was a tendency to be associated between CADD score and age at onset (*p* = 0.01).

![Relationship between predicted pathogenicity of mutations and age at onset\
Graph showing the distribution of the age at onset of the DBP deficiency (infant \[n = 36\], juvenile \[n = 6\], and adult \[n = 3\]) from this study and previous literature. The score of p.Ala175Thr is indicated as a red dot. CADD = Combined Annotation-Dependent Depletion; DBP = D-bifunctional protein.](NG2019010918f5){#F5}

Discussion {#s3}
==========

Our study is the report on middle age--onset DBP deficiency and revealed that *HSD17B4*, a causative gene of DBP deficiency, induced a middle age--onset slowly progressive SCAR. We also obtained biochemical, immunocytochemical, and structural modeling data to confirm the pathophysiology. Moreover, by comparing with previous data, we indicated that CADD scores may be used to estimate the severity of a DBP deficiency.

Two families were independently screened for a genetic mutation associated with SCAR. *HSD17B4* was the only common candidate for both families and was located in the IBD segment with the shared haplotype. The CADD score of the p.Ala175Thr mutation was low. However, the p.Ala175Thr mutation was previously reported as a compound heterozygous mutation.^[@R7]^ We conducted the following analysis to investigate the pathogenicity of p.Ala175Thr homozygous mutation of *HSD17B4*.

First, we performed an in vitro assay with fibroblasts. Although the abundance of the DBP protein was reduced, the expression of the messenger RNA (mRNA) was normal. In addition, although DBP protein localization in peroxisomes was normal, the amount of DBP in the peroxisomes decreased. Moreover, the BN-PAGE analysis revealed that levels of dimerized DBP, the protein\'s functional form, were diminished in the patients. These data indicate that the steady-state level of DBP protein was impaired. Next, structural modeling assessment also suggests that p.Ala175Thr potentially affects the dimerization of DBP. Thus, the quantitative reduction in functional DBP in the patients could explain the pathogenicity of the homozygous *HSD17B4* mutation.

The main clinical features of our patients were cerebellar ataxia, sensorineural hearing loss, and mild peripheral neuropathy. In these patients, disease onset occurred in middle age, which was an older onset age than that described in previous reports. We compared the symptoms exhibited by our patients with those of previously reported patients and classified the cases into 3 groups according to the age of DBP deficiency onset ([table 1](#T1){ref-type="table"}). Our cases were included in the adult-onset group. The infant-onset group shows the most severe clinical features and death before age 2 years and is characterized by cortical malformation, seizure, hepatomegaly, and hypotonia. Some patients with infant-onset DBP deficiency exhibit milder features, primarily linked to leukodystrophies, which permit survival into childhood. In contrast, juvenile- and adult-onset groups are much milder than infant onset. Unlike infant onset, juvenile and adult onset have cerebellar ataxia as the main symptom. Although there are some similarities between both juvenile- and adult-onset groups, notable differences exist. Intellectual disability, retinopathy, and pyramidal signs are seen in many cases of juvenile onset, whereas pure cerebellar ataxia, in addition to deafness, tends to be observed in most cases of adult onset. Infertility in the adult-onset group is milder and less frequent than in the juvenile-onset group. A few cases of adult onset present intellectual disability, but these symptom seems to be caused by hearing loss.

As mentioned above, we performed biochemical analyses and compared the results with previous reported data. The infant-onset group features depletion of both the HSD17B4 protein and mRNA expression.^[@R18],[@R27]^ In relatively mild cases of infant-onset, RNA expression was significantly lower than that in controls; patients with severe disease exhibited even lower levels of RNA expression.^[@R27]^ In both severe and mild cases of infant onset, the proteins were not detected. Even among cases of infant onset, a slight residual DBP could account for the survival of the patients.^[@R18]^ In vivo experiments provide additional supporting evidence that knock-out mice show severe growth retardation during the first weeks of life, resulting in the premature death of one-third of the affected mice.^[@R28]^ In juvenile-onset DBP deficiency, a remarkable reduction in HSD17B4 mRNA and protein has been observed in patients\' fibroblasts and lymphoblasts and overexpressed HEK293T cells with a mutant *HSD17B4*.^[@R4],[@R8],[@R9],[@R11]^ In adult-onset cases, the levels of mRNA expression were normal, and the expression levels of DBP remained moderate. The impaired enzyme activities result from dysfunction or reduction of the protein, but our data suggest that the delayed onset of disease may be attributed to the remaining DBP protein function. These pathophysiologic features could represent differences in the 3 groups based on age at onset.

The pathogenicity of the identified mutation was evaluated in each age-onset group with CADD, and the scores of each of the 3 groups were compared ([figure 5](#F5){ref-type="fig"}). We analyzed the correlation with the age at onset using the average CADD score of both alleles and the lower CADD score. The lower CADD scores were more associated with disease severity. The CADD score of the identified mutation, Ala175Thr, was low, which is consistent with the milder symptom severity presented in the older-onset group. Therefore, CADD scores could estimate the severity of the DBP deficiency with a certain degree of accuracy.

Our results indicate that a homozygous mutation of *HSD17B4* was responsible for slowly progressive SCAR. The data on the oldest cases of DBP deficiency hitherto reported broaden the scope of DBP deficiency phenotypes.
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